NCT05083130 is a NA clinical trial of a wake prone positioning in COVID-19, sponsored by Oxford University Clinical Research Unit, Vietnam.

Who is sponsoring NCT05083130?

NCT05083130 is sponsored by Oxford University Clinical Research Unit, Vietnam.

What drugs are being tested in NCT05083130?

Interventions in NCT05083130: a wake prone positioning.

What condition does NCT05083130 study?

NCT05083130 studies COVID-19, SARS-CoV2 Infection, COVID-19 Acute Respiratory Distress Syndrome, Acute Hypoxemic Respiratory Failure, Respiratory Distress Syndrome, Adult.

Is NCT05083130 still recruiting?

NCT05083130 is currently completed. Last updated 7 June 2023.

Last reviewed 2023-06-07 · How we verify

NCT05083130

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Awake Prone Positioning in Moderate to Severe COVID-19

Completed NA Last updated 7 June 2023

What this trial tests

NA trial testing a wake prone positioning in COVID-19 in 93 participants. Completed in 1 May 2023.

Timeline

8 March 2022

Primary endpoint
31 March 2023

1 May 2023

Quick facts

Lead sponsor	Oxford University Clinical Research Unit, Vietnam
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	93
Start date	8 March 2022
Primary completion	31 March 2023
Estimated completion	1 May 2023
Sites	1 location across Vietnam

Drugs / interventions tested

a wake prone positioning

Conditions studied

COVID-19 — all drugs for COVID-19 →
SARS-CoV2 Infection — all drugs for SARS-CoV2 Infection →
COVID-19 Acute Respiratory Distress Syndrome — all drugs for COVID-19 Acute Respiratory Distress Syndrome →
Acute Hypoxemic Respiratory Failure — all drugs for Acute Hypoxemic Respiratory Failure →

Sponsor

Oxford University Clinical Research Unit, Vietnam

Who can join

18 and older, any sex, with COVID-19 or SARS-CoV2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is comparing vital signs between standard care and prone position groups. Standard care will consist of routine clinical care, including any advice to lie in prone position as routinely recommended by participating sites. For those randomized to prone position, a special intervention team will visit patients' rooms aiming for patients to maintain the prone position for at least 8 hours a day.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Awake prone positioning effectiveness in moderate to severe COVID-19 a randomized controlled trial.
Phong NT, Duc DH, Hai HB, Nguyen NT, et al · · 2024 · cited 3× · PMID 39654551 · DOI 10.12688/wellcomeopenres.22792.2
Awake prone positioning effectiveness in moderate to severe COVID-19 a randomized controlled trial.
Phong NT, Duc DH, Hai HB, Nguyen NT, et al · · 2024 · DOI 10.12688/wellcomeopenres.22792.2
Awake prone positioning effectiveness in moderate to severe COVID-19 a randomized controlled trial
Phong NT, Duc DH, Hai HB, Nguyen Thanh N, et al · · 2024 · DOI 10.1101/2024.06.30.24309722

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Oxford University Clinical Research Unit, Vietnam trials

Trials by the same sponsor.

NCT07543458 — Therapeutics for Moderate and Severe Dengue · Phase 3 · not yet recruiting
NCT06551844 — Adaptive Dengue Antiviral Platform Trial · Phase 2 · not yet recruiting
NCT05909384 — Management of Sepsis in Resource Limited Settings Using a Delphi Method. · completed
NCT05611710 — Anakinra in Dengue With Hyperinflammation ( AnaDen ) · Phase 2 · active not recruiting
NCT04349826 — The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial) · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05083130 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oxford University Clinical Research Unit, Vietnam
Last refreshed: 7 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05083130.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing